Friday, February 1, 2019

Hot Bank Stocks To Buy Right Now

tags:NTC,MLI,VRX, When the cat is away, the mice shall play. Hat tip to TheStreet's John Pickering, who wrote that with Donald Trump chilling at his Florida resort this week the market has been able to rally. Coincidence? Probably not. With Trump out of the way, the market has been able to focus on the decent round of earnings that have started to trickle in. To that end, the market has a new earnings report it must seriously consider before rallying into the weekend.

IBM's (IBM) margin disappointment was putting pressure on shares Wednesday. While it appears to be company-specific, the fact the market is overlooking a 3-cent earnings beat from Big Blue -- and solid beats by banks like Action Alerts PLUS holding Goldman Sachs (GS) -- is a short-term bearish indicator.

Hot Bank Stocks To Buy Right Now: Nuveen Connecticut Premium Income Municipal Fund(NTC)

Advisors' Opinion:
  • [By Logan Wallace]

    Media stories about Nuveen Connecticut Premium Income Mun Fd (NYSE:NTC) have trended very positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuveen Connecticut Premium Income Mun Fd earned a news sentiment score of 0.53 on Accern’s scale. Accern also gave news stories about the investment management company an impact score of 47.4041994466706 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Hot Bank Stocks To Buy Right Now: Mueller Industries, Inc.(MLI)

Advisors' Opinion:
  • [By Ethan Ryder]

    Mueller Industries, Inc. (NYSE:MLI) Director Scott Jay Goldman bought 1,000 shares of Mueller Industries stock in a transaction dated Friday, August 24th. The stock was acquired at an average cost of $33.24 per share, with a total value of $33,240.00. Following the transaction, the director now owns 11,000 shares of the company’s stock, valued at approximately $365,640. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

  • [By Max Byerly]

    Systematic Financial Management LP grew its position in Mueller Industries, Inc. (NYSE:MLI) by 6.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 491,916 shares of the industrial products company’s stock after purchasing an additional 28,784 shares during the quarter. Systematic Financial Management LP owned about 0.85% of Mueller Industries worth $14,516,000 at the end of the most recent reporting period.

  • [By Shane Hupp]

    Voya Investment Management LLC decreased its holdings in Mueller Industries, Inc. (NYSE:MLI) by 8.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,856 shares of the industrial products company’s stock after selling 1,999 shares during the period. Voya Investment Management LLC’s holdings in Mueller Industries were worth $674,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Mueller Industries (NYSE:MLI) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

  • [By Ethan Ryder]

    Swiss National Bank grew its position in shares of Mueller Industries, Inc. (NYSE:MLI) by 3.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,400 shares of the industrial products company’s stock after buying an additional 3,100 shares during the period. Swiss National Bank owned about 0.17% of Mueller Industries worth $2,496,000 as of its most recent SEC filing.

Hot Bank Stocks To Buy Right Now: Valeant Pharmaceuticals International Inc(VRX)

Advisors' Opinion:
  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its most recent quarterly report before the markets opened on Tuesday. At the same time, the firm announced that it would also be changing its name sometime in the very near future.

  • [By Dan Caplinger]

    The stock market finally hit some resistance on Tuesday, giving up ground and breaking a long streak of consecutive advances for most major benchmarks. Market participants got spooked by a rise in interest rates, with 10-year Treasury yields once again climbing above the 3% mark and leading some to predict even steeper advances in the future. With budget deficits ballooning, higher interest expenses on the national debt could have a dramatic impact on the U.S. economy, especially if it lures investors away from high-flying stocks. Yet even amid the bond-driven downturn, some individual companies saw good news lift their shares. Valeant Pharmaceuticals International (NYSE:VRX), Hollysys Automation Technologies (NASDAQ:HOLI), and Ascena Retail Group (NASDAQ:ASNA) were among the best performers on the day. Here's why they did so well.

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) has a PDUFA action date set for October 5 for its Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks.

  • [By Logan Wallace]

    Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) – Analysts at Jefferies Group reduced their Q3 2018 earnings per share (EPS) estimates for shares of Valeant Pharmaceuticals International in a research report issued to clients and investors on Tuesday, May 8th. Jefferies Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will earn $0.70 per share for the quarter, down from their prior forecast of $0.73. Jefferies Group currently has a “Buy” rating and a $23.00 target price on the stock. Jefferies Group also issued estimates for Valeant Pharmaceuticals International’s Q4 2018 earnings at $0.71 EPS and FY2022 earnings at $5.50 EPS.

No comments:

Post a Comment